ENHANCEMENT OF CELL MEDIATED IMMUNITY THROUGH NON-SPECIFIC IMMUNOSTIMULATION WITH LIPOSOME ENCAPSULATED GAMMA-INTERFERON (U)

BY

J.P. WONG,
B. KOURNIKAKIS,
E.G. SARAVOLAC*, AND
L.C. GORTON**

* DRES POSTDOCTORAL FELLOW 1992
** DRES SUMMER RESEARCH ASSISTANT 1989

APRIL 1994

WARNING

The use of this information is permitted subject to recognition of proprietary and patent rights.
Enhancement of Cell Mediated Immunity through Non-Specific Immunostimulation with Liposome Encapsulated Gamma-Interferon.

by

J.P. Wong, B. Kournikakis, E.G. Saravolac†, and L.C. Gorton‡.

† DRES Postdoctoral Fellow 1992
‡ DRES Summer Research Assistant 1989

UNCLASSIFIED 94 5 24 026
The ability of liposome-encapsulated gamma interferon (LIP-\(\gamma\) IFN) to stimulate mouse cell-mediated immunity was assessed both in vivo and in vitro. The enhancement of the cell-mediated immune response was demonstrated in vitro by a chemiluminescent assay which measured the phagocytic activity of peritoneal macrophages. Peritoneal macrophages harvested from mice treated with gamma interferon (\(\gamma\) IFN) or muramyl dipeptide showed significant increases in both macrophage yield as well as in ability to phagocytize zymosan particles. However, when treated with \(\gamma\) IFN encapsulated within liposomes both macrophage yield and phagocytic activity further increased by at least 100% over unencapsulated \(\gamma\) IFN. Using the in vivo influenza mouse protection model, intranasally administered LIP-\(\gamma\) IFN resulted in a 70% survival rate to mice challenged intranasally with 10 LD\(_{50}\) doses of influenza A/PR/8 virus compared with a 20% survival rate with free \(\gamma\) IFN. Together these results suggest that liposome encapsulation increases \(\gamma\) IFN efficacy in providing non-specific stimulation of the cell-mediated immune system.

La capacité de l'interféron gamma encapsulé dans des liposomes (LIP-\(\gamma\) IFN) de stimuler l'immunité à médiation cellulaire chez la souris a été évaluée in vivo et in vitro. L'accroissement de la réponse anticorps à médiation cellulaire a été mis en évidence in vitro par un test de chimioluminescence permettant de mesurer l'activité phagocytaire des macrophages péritonéraux. Les macrophages péritonéraux récoltés chez les souris traitées avec l'interféron gamma (\(\gamma\) IFN) ou le muramyl dipeptide ont présenté une augmentation substantielle tant du rendement en macrophage que de leur capacité de phagocyter des particules de zymosan. Toutefois, le traitement par \(\gamma\) IFN encapsulé dans des liposomes a fait augmenter ces deux paramètres d'au moins 100 p. 100 par rapport aux valeurs obtenues avec l'\(\gamma\) IFN non encapsulé. Dans le modèle murin de protection contre la grippe in vivo, le LIP-\(\gamma\) IFN administré par voie intranasale a fait augmenter à 70 p. 100 le taux de survie des souris exposées par voie intranasale à des doses de l'ordre de 10 LD\(_{50}\) du virus grippal A/PR/8, comparativement à un taux de survie de 20 p. 100 avec l'\(\gamma\) IFN seul. Ces résultats indiquent que l'encapsulation dans des liposomes augmente l'efficacité de l'\(\gamma\) IFN en ce qui a trait à la stimulation non spécifique du système immunitaire à médiation cellulaire.
Table of Contents

Abstract ........................................................................................................................ i
Table of Contents ........................................................................................................ ii
Introduction ................................................................................................................ 1
Materials and Methods ............................................................................................. 2
Results ......................................................................................................................... 6
Discussion .................................................................................................................... 7
References .................................................................................................................... 10
Tables ........................................................................................................................... 13
Figure .......................................................................................................................... 16
INTRODUCTION

Immunotherapy has played an increasingly important role in clinical applications in recent years particularly where the immune therapy of AIDS and cancer are concerned [2]. However it appears that this approach has not been fully exploited for the prevention and treatment of viral, bacterial and infectious diseases. Immunotherapy may be categorized in two broad classes, specific and non-specific. Specific immunotherapy provides specific immunity to particular antigens using active immunization or adoptive transfer of sensitized lymphoid cells of specific immunoglobulins from immunized donors. In non-specific immunotherapy, the immune system of the host is normally enhanced by the administration of immunomodulators and thus has the potential to provide a general prophylaxis against a wide spectrum of infectious microorganisms. The ability to enhance immune competence is particularly significant in the defence against biological warfare (BW) agents as it may be possible to defend the host against a range of infectious entities; viral, bacterial or parasitic.

Immunomodulators such as gamma interferon (γIFN), macrophage activating factor or muramyldipeptide (MDP) operate by activating macrophages and as such yield an immunomodulated state reflected by the increase in the phagocytic function of these cells [6,7]. Macrophages are the body's primary line of natural defence against microbial infections. In addition to their ability to phagocytise microorganisms, macrophages play an essential role in humoral immunity by processing and presenting antigens to T-lymphocytes [3]. The use of immunomodulators to stimulate macrophage activity in vivo is confounded by a number of factors. Certain immunomodulators such as γIFN do not enter target tissues efficiently [18] or are rapidly cleared from the general circulation and body following systemic administration [13,16].

In order to circumvent these effects immunomodulators may be incorporated into liposomes. Liposomes are microscopic lipid vesicles which have a number of characteristics making them an attractive carrier/delivery system for immunotherapeutic agents [4,16]. Immunomodulators may be encapsulated within liposomes and thus be protected from in vivo degradation and dilution [13,14]. Agents are readily released from liposomes in a gradual and sustained manner thus increasing their prophylactic/therapeutic
Liposomes while reducing their intrinsic toxicities [13,20]. In addition, liposomes are particularly well suited as carriers of macrophage stimulating agents as they are preferentially taken up by the macrophages upon systemic, pulmonary or peritoneal administration and thus the immunomodulators can be delivered to these macrophages in concentrated levels [4,16].

This study evaluates the effectiveness of liposomes in potentiating the immunomodulation effect of γIFN. The stimulation of macrophage phagocytic activity by these immunomodulators in the mouse peritoneum is first assessed. Following that, the ability of pulmonary delivered liposome encapsulated and non-encapsulated γIFN's are compared for prophylactic efficacy in the resistance of the mouse against an influenza virus.

MATERIALS AND METHODS

Materials. Gamma interferon was purchased from Boehringer Mannheim Canada (Dorval, PQ). Muramyldipeptide and all phospholipids and cholesterol used for the study were purchased from Sigma Chemical Co. (St. Louis, Mo.).

RPMI 1640 with glutamine was purchased from Flow Laboratories Inc. (Mississauga, Ont.) and was prepared by adding 2.0 g of sodium bicarbonate per litre of RPMI 1640. Lavage fluid for peritoneal washes (100 mL) contained 90 mL RPMI 1640, 10 mL fetal bovine serum (FBS)(Flow Laboratories, Mississauga, Ont.) and 0.0738 g sodium chloride. Harvested cells were washed in RPMI 1640 with 10% FBS. These solutions were filter sterilized with a 0.45 μm Nalgene filter (Nalge Company, Rochester, NY.) and stored at 4°C.

Zymosan was prepared by suspending 150 g of zymosan (Sigma Chemical Co.) in 30 mL of phosphate buffered saline (PBS), pH 6.75) (Oxoid Canada, Ottawa, Ont.) and the suspension was boiled for 30 min. PBS was then added to restore the total volume to 30 mL. Ten mL aliquots were pelleted by centrifugation at 300 x g for 10-15 min in a Beckman TJ-6 centrifuge. Activated zymosan was prepared by incubating the zymosan
pellet at 37°C for 30 min with 2-3 mL normal human serum obtained from healthy adult volunteers. After incubation with the serum, the suspension was re-centrifuged as described above. The activated zymosan pellets were resuspended in 50 mL of RPMI to yield a working concentration of 1 mg/mL.

Animals. Six week old female Balb/c mice were purchased from Charles River Canada (St. Constant, PQ). Mice were acclimated for one week in the DRES vivarium before use and used over a four week period. Care and handling of mice followed guidelines set out by the Canadian Council on Animal Care.

Liposome Preparation. Liposomes used in this study for the encapsulation of γIFN were prepared using a modification of the freeze-drying method described by Kirby and Gregoriadis [8]. Negatively charged liposomes were prepared using phosphatidylcholine: cholesterol: phosphatidylserine in a molar ratio of 7:2:1. Briefly, a total of 20 μmoles of the lipids in chloroform:methanol (2:1, v/v) were dried by heating at 45°C. Throughout this procedure, the contents of the tube was purged whenever possible with a gentle stream of dry nitrogen. The lipids were further dried for 30 min in a vacuum oven to remove residual organic solvent. The lipids were then rehydrated with 1 mL of distilled water. The γIFN to be encapsulated (total volume of 400 μL, 100,000 U/mL) was then added to the lipid mixture and freeze-dried overnight. The mixture was reconstituted in 100 μL of 100 mM HEPES buffer in normal saline, pH 6.7 and vortexed for 2-3 min. After leaving the reconstituted liposomes at room temperature for 1 hr, they were washed with 8 mL of HEPES buffer and ultracentrifuged at 125,000 x g for 30 min at 4°C in a Beckman L8-70 ultracentrifuge fitted with a 70.1 Ti rotor. HEPES buffer was used to wash the pellet and then the liposomes were ultracentrifuged again as described above. The liposome pellet was reconstituted in 1 mL of HEPES buffer. The liposomes were negatively stained with 2% sodium phosphotungstate (pH 7.4) and the morphology and vesicle size distribution were analyzed by electron microscopy. Liposomes prepared using this method were found to be heterogeneous in size with the vesicle diameters ranging from approximately 300 nm to 2 μm.
**Macrophage Isolation.** Peritoneal macrophages were prepared by a modification of the procedure described by Mishell and Shiigi [11]. The recovered lavage fluid for each mouse was pooled. The lavage fluid was then centrifuged at 160 × g for 7 min. The resulting cell pellet was resuspended in RPMI 1640 plus 10% FBS and centrifuged again as described above. The washed pellet was resuspended in RPMI 1640 to a final volume of 3 mL. The cell suspension was then layered onto 3 mL of Histopaque 1083 (Sigma Chemical Co.) and centrifuged at 700 × g for 30 min. The macrophages were collected by removing the cells at the density gradient interface by aspiration with a Pasteur pipet. The cells were suspended in RPMI 1640 to a final volume of 13 mL and centrifuged at 450 × g for 10 min. The pellet was resuspended in 1-1.5 mL of RPMI 1640 and viable cells were counted by Trypan Blue dye exclusion. The isolated cells were visually identified as macrophages. Slides were prepared by centrifuging the 0.5 mL of purified sample onto glass slides using a Cytospin 2 centrifuge (Shandon Southern Products Ltd. Astmoor, U.K.). After the slides were left to dry overnight, the preparation was stained with STAT STAIN (VWR Scientific Inc., Brisbane, CA.). The samples were examined on a microscope using oil immersion (1000 × magnification).

**Chemiluminescence Assay.** A macrophage concentration of 2 × 10^6 cells/mL of RPMI 1640 was used in the assay. Four hundred μl of cells plus 20 μl of 0.002 M lucigenin (Sigma Chemical Co.) was pipetted into a cuvette and placed in an LKB 1251 luminometer (LKB, Stockholm, Sweden) set at 37°C. The luminometer controlled dispensers delivered 200 μl of RPMI 1640, or activated zymosan to each sample at time zero of the assay. The total chemiluminescence (measured in mV) was recorded over a 15 sec period at 2-3 min intervals for each sample for up to 2 hr.

**Adaptation of egg-propagated influenza A/PR/8 in mice.** Influenza A/PR/8 virus was adapted in mice by four blind passages using egg-propagated virus (ATCC, Parklawn,
MD.) as the initial inoculum. For each passage, BALB/c mice, anaesthetized with sodium pentobarbital (50 mg/kg body weight, i.p.), were inoculated intranasally with 50 µl of egg-propagated virus for the initial passage. At four days post infection, the mice were sacrificed and the lungs aseptically removed. The lungs were then homogenized in a tissue grinder with a mixture of 5 g sterile aluminium hydroxide powder and 10 mL phosphate buffered saline, pH 7.2 containing penicillin-G (100 µg/mL), fungizone (0.25 µg/mL) and streptomycin sulphate (100 µg/mL). The ground lung extract was then centrifuged at 5000 × g for 15 min and the supernatant was used for re-inoculation into mice in subsequent passages. The supernatant from the fourth and final passage was inoculated into the allantoic cavity of embryonated hens’ eggs and the eggs were incubated at 37°C for 4-5 days. The allantoic fluids were then isolated and pooled. The pooled allantoic fluid was assayed for virus infectivity by a mouse LD₅₀ assay.

**LD₅₀ Determination for mouse-adapted influenza A virus.** Pooled allantoic fluid from embryonated eggs infected with lung extract from the fourth passage in mice was diluted serially in sterile PBS. Balb/c mice, anesthetized with an intraperitoneal injection of sodium pentobarbitol (50 mg/kg body weight), were inoculated intranasally with 50 µl of the virus dilutions (8 mice per group). At day 14 post infection, the number of mice which had survived the virus infection was recorded. The LD₅₀ value was calculated by the method of Reed and Muench [1].

**Influenza protection.** The volume for intranasal administration of LIP-γIFN was 50 µl. For intranasal administration, mice were anesthetized with sodium pentobarbitol as described above. When the animals were unconscious, they were carefully supported by hands with their nose up, and the material to be administered was gently applied with a micro-pipettor into the nostrils. The applied volume was naturally inhaled into the lungs.

In the study of prophylactic treatment of mice against influenza A infection with interferon, groups of sodium pentobarbatol anesthetized mice (10 mice per group) were inoculated intranasally with either 50 µl γIFN (1000 U per mouse), γIFN encapsulated within liposomes (LIP-γIFN 1 µmol total lipid containing 1000 U γIFN per mouse, or with sham liposomes (sham LIP, 1 µmole total lipid per mouse, no γIFN). The mice were
pre-treated at 24 hour intervals beginning at either 1, 2, 3, or 4 days before intranasal challenge with 10 LD50 of mouse-adapted influenza A/PR/8 virus. At day 14 post virus challenge, the number of mice surviving the virus challenge was recorded.

Statistics. Statistical comparisons of the mortality and survival rates among groups of mice were performed by one-way analysis of variance (ANOVA), and were calculated using the Multivariate General Linear Hypothesis (MGLH) module of Systat computer software program (Evanston, IL.).

RESULTS

Macrophage Isolation. The average yield of macrophages from both immunomodulator-treated and control mice is shown in Table I. Treatment with an immunomodulator (MDP or γIFN) or with sham liposomes increased the macrophage yield over 3-fold. Mice receiving liposome encapsulated γIFN gave the highest yield with nearly a 5-fold increase over the PBS control group.

Macrophage Stimulation. Activation of peritoneal macrophage phagocytic activity was measured by the chemiluminescence assay. Activation of phagocytic activity was observed with both MDP and γIFN. Activation of peritoneal macrophages from MDP-treated mice was not detectable until after two days post treatment (Figure 1). Activation of macrophages isolated from γIFN treated mice was evident at both 1 and 2 days post-treatment but after 3 days phagocytic activity decreased to near control levels (Figure 2). Activation of peritoneal macrophages from mice treated with liposome-encapsulated γIFN was more pronounced than that of both mice treated with PBS or with free γIFN. At 24 hours post-treatment LIP-γIFN was shown to be more effective than γIFN or LIP alone (Figure 3).

LD50 Determination for mouse-adapted influenza A virus. The LD50 determination in mice infected intranasally with mouse-adapted influenza A/PR/8 is shown in Table II. All mice infected with the mouse-adapted virus at a dilution of 10^-5 or lower died from the infection. The LD50, calculated by the method of Reed and Munch, was 10^-5.21. The
50% survival time, defined as the time by which 50% of the mice died from infection with 10 LD₅₀ of the virus, was found to be around 7 days.

**Interferon-Mediated Influenza Protection.** The efficacies of free and liposome-encapsulated γIFN in protection against influenza A infection were compared in the following experiments. Groups of mice were pretreated with either PBS, sham LIP, free γIFN or LIP-γIFN on various days prior to intranasal infection with 10 LD₅₀ of influenza A virus. As summarized in Table III, groups of 10 mice pretreated with either PBS or sham LIP were completely unprotected against infection with the influenza virus. When treated with free or unencapsulated γIFN there was a small but significant, 20% survival rate in the groups of mice only after 3-4 repeated doses at 24 hour intervals before viral inoculation. Mice pretreated with LIP-γIFN had the greatest survival rate. A single dose of LIP-γIFN was as effective as 3-4 doses of γIFN (ie. 20% survival). Repeated intranasal doses of LIP-γIFN 2 to 4 days prior to inoculation with influenza virus resulted in survival rates of 50 to 70%. The LIP-γINF had its highest efficacy when administered in three doses at 24 hour intervals prior to infection with influenza A resulting in a 70% survival rate (Table III).

**DISCUSSION**

Interferons are unique hormone-like proteins which have non-specific antiviral and immunomodulatory activities [6,7]. The antiviral activity results from the ability of interferon to induce the synthesis of host proteins which inhibit viral replication. Interferon also enhances a number components of cellular immunity including, expression of histocompatibility antigens, natural killer cell activity of lymphocytes and antibody-dependent cell-mediated cytotoxicity [7]. These features make it an ideal candidate for prophylaxis against wide variety of infectious and BW agents. For example, three interferon types have recently been shown to protect mice from a wide range of virus species [15]. In addition, previous studies have suggested a role for free interferon for prophylaxis against respiratory disease [12] However, since this protein is a small protein it is subject to clearance and degradation from the body in a relatively short period of
time [13]. The results of this study demonstrate how the efficacy of γINF’s antiviral and immunomodulatory activity could be enhanced by encapsulation into liposomes.

In the first instance we have demonstrated in vitro that immunomodulators can be used to elicit a general, non-specific immune response to the hosts in which they are introduced. Studies measuring enhanced phagocytic activity of peritoneal macrophages demonstrates that the effect is a general feature of different types of immunomodulator and not just a specific artifact of γIFN. It is interesting to note that there was a significant increase in the peritoneal macrophage yield upon administration of sham liposomes to the peritoneum. While subsequent in vivo data does not suggest this results in an increased protection against viral infection, this phenomenon may be important where conditions requiring increased macrophage numbers or activity is required. Where encapsulated γIFN was administered there was the largest increase in both macrophage number and phagocytic activity.

Secondly, the in vivo experiments have demonstrated that the efficacy of γIFN for protection against infection by influenza A virus is enhanced by liposome encapsulation. Protection against influenza mortality could be detected in mice pretreated with free and liposome encapsulated γIFN. However, LIP-γIFN after 1 day of pretreatment was as effective as 3-4 days of pretreatment of free γIFN. Three days of pretreatment with LIP-γIFN resulted in up to 70% survival of infected mice after 14 days. This remarkable increase in γIFN efficacy is likely to be the result of the increased retention of γIFN in the lungs afforded by liposome encapsulation. Indeed, radiotracer studies using 125I-IgG indicated that lung retention of liposome-encapsulated IgG was 3-fold more than unencapsulated IgG even at 24 hr post administration [20]. The observed decrease in survival after 4 days of LIP-γIFN pretreatment may reflect a narrow optimum dose range for γIFN which has been observed when the non-encapsulated form was used in humans [10]

Administration of γIFN to the host in this manner significantly delays the onset of the morbidity and mortality associated with the viral disease. A major benefit of this form of treatment is that it allows the host immune system time to elicit a natural specific immune response to fight the infection. Such an advantage could be most significant in
the protection of personnel exposed to infectious BW agents. However one of the major
drawbacks of interferon therapy is that interferons are toxic molecules which can cause
severe toxicities to the central nervous system, renal and cardiac functions [7, 19].
Liposome encapsulation may prove extremely valuable in interferon immunotherapy
because liposomes could dramatically reduce interferon toxicities through their slow
release characteristics. Valuable information may be obtained from future studies were
liposome encapsulated γIFN may be administered both prior to and during the course of
viral infections caused by influenza or possibly other potential BW agents of viral nature.
Additional studies are also required pertaining to various mechanisms to deliver the
liposome encapsulated drugs in a form appropriate for human use.
REFERENCES


# TABLE I

Yield of peritoneal macrophages following administration of free or liposome-encapsulated immunomodulators

<table>
<thead>
<tr>
<th>Test Group</th>
<th>Cells Harvested per Mouse ($10^6$)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PBS Control</td>
<td>1.1 ± 0.6</td>
</tr>
<tr>
<td>MDP</td>
<td>3.7 ± 1.6</td>
</tr>
<tr>
<td>Free γIFN</td>
<td>2.5 ± 1.4</td>
</tr>
<tr>
<td>Sham liposomes</td>
<td>3.7 ± 1.6</td>
</tr>
<tr>
<td>LIP-γIFN</td>
<td>5.3 ± 2.0</td>
</tr>
</tbody>
</table>

± standard deviation of the mean
<table>
<thead>
<tr>
<th>Log of Virus Dilution</th>
<th>No. of Survivors at Day 14 post virus challenge</th>
<th>% Mortality</th>
</tr>
</thead>
<tbody>
<tr>
<td>-4</td>
<td>0/8</td>
<td>100</td>
</tr>
<tr>
<td>-5</td>
<td>0/8</td>
<td>100</td>
</tr>
<tr>
<td>-6</td>
<td>5/8</td>
<td>37</td>
</tr>
<tr>
<td>-7</td>
<td>8/8</td>
<td>0</td>
</tr>
</tbody>
</table>
TABLE III

The effect of γIFN and LIP-γIFN pretreatment on the protection of mice against intranasal challenge with 10 LD$_{50}$ of mouse adapted influenza A virus.

<table>
<thead>
<tr>
<th>Group</th>
<th>Days Before Infection</th>
<th>No. of Survivors at day 14 post infection</th>
<th>% Survival</th>
</tr>
</thead>
<tbody>
<tr>
<td>PBS</td>
<td>3, 2, 1</td>
<td>0/10</td>
<td>0</td>
</tr>
<tr>
<td>Sham LIP</td>
<td>3, 2, 1</td>
<td>0/10</td>
<td>0</td>
</tr>
<tr>
<td>γIFN</td>
<td>1</td>
<td>0/10</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>2, 1</td>
<td>0/10</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>3, 2, 1</td>
<td>2/10</td>
<td>20</td>
</tr>
<tr>
<td></td>
<td>4, 3, 2, 1</td>
<td>2/10</td>
<td>20</td>
</tr>
<tr>
<td>LIP-γIFN</td>
<td>1</td>
<td>2/10</td>
<td>20</td>
</tr>
<tr>
<td></td>
<td>2, 1</td>
<td>5/10</td>
<td>50</td>
</tr>
<tr>
<td></td>
<td>3, 2, 1</td>
<td>7/10</td>
<td>70</td>
</tr>
<tr>
<td></td>
<td>4, 3, 2, 1</td>
<td>6/10</td>
<td>60</td>
</tr>
</tbody>
</table>
Chemiluminescence assay of mice treated with MDP. Treatment with free MDP. The cell concentrations used in the assay are $4.06 \times 10^6$ cells/ml (PBS control, 24 hr), $4.06 \times 10^6$ cells/ml (MDP, 24 hr), $4.11 \times 10^6$ cells/ml (MDP, 48 hr) and $3.26 \times 10^6$ cells/ml (MDP, 72 hr).
Chemiluminescence assay of mice treated with free IFN-γ. The cell concentrations used in the assay were 2.15 x 10^6 cells/ml (PBS control, 18 hr), 2.3 x 10^6 cells/ml (IFN-γ, 18 hr), 2.67 x 10^6 cells/ml (IFN-γ, 42 hr) and 2.73 x 10^6 cells/ml (IFN-γ, 72 hr).
Chemiluminescence assay of mice treated with IFN-γ and LIP-IFN-γ. The cell concentrations used in the assay for the sham-LIP, IFN-γ, and LIP-IFN-γ were 2.3 x 10^8 cells/ml. In each assay, Macrophage phagocytic activity was assayed 18 hr post treatment. Phagocytic activity was assayed as described in materials and methods.
**Enhancement of Cell-Mediated Immunity through Non-Specific Immunostimulation with Liposome Encapsulated Gamma-Interferon**

**Wong, J.P.; Kournikakis, B; Saravolac, E.G.; and Gorton, L.C.**

**DATE OF PUBLICATION** (month and year of publication of document)

April 1994

**NO. OF PAGES** (total containing information, include Annexes, Appendices, etc.)

27

**NO. OF REFS** (total cited in document)

20

**SPONSORING ACTIVITY** (the name of the department project office or laboratory sponsoring the research and development. Include the address)

Defence Research Establishment Suffield

**ORIGINATOR** (the name and address of the organization preparing the document. Organizations for whom the document was prepared, e.g. Establishment sponsoring a contractor's report, or tasking agency, are entered in section 8.)

Defence Research Establishment Suffield

**PROJECT OR GRANT NO.** (if appropriate, the applicable research and development project or grant number under which the document was written. Please specify whether project or grant)

351SH

**ORIGINATOR'S DOCUMENT NUMBER** (the official document number by which the document is identified by the originating activity. This number must be unique to this document)

SR 584

**DOCUMENT AVAILABILITY** (any limitations on further dissemination of the document, other than those imposed by security classification)

- Unlimited distribution
- Distribution limited to defence departments and defence contractors; further distribution only as approved
- Distribution limited to defence departments and Canadian defence contractors; further distribution only as approved
- Distribution limited to government departments and agencies; further distribution only as approved
- Distribution limited to defence departments; further distribution only as approved
- Other (please specify):
The ability of liposome-encapsulated gamma interferon (LIP-γIFN) to stimulate mouse cell-mediated immunity was assessed both in vivo and in vitro. The enhancement of the cell-mediated immune response was demonstrated in vitro by a chemiluminescent assay which measured the phagocytic activity of peritoneal macrophages. Peritoneal macrophages harvested from mice treated with gamma interferon (γIFN) or muramyldipeptide showed significant increases in both macrophage yield as well as in ability to phagocytize zymosan particles. However, when treated with γIFN encapsulated within liposomes both macrophages yield and phagocytic activity further increased by at least 100% over unencapsulated γIFN. Using the in vivo influenza mouse protection model, intranasally administered LIP-γIFN resulted in a 70% survival rate to mice challenged intranasally with 10 LD50 doses of influenza A/PR/8 virus compared with a 20% survival rate with free γIFN. Together these results suggest that liposome encapsulation increases γIFN efficacy in providing non-specific stimulation of the cell-mediated immune system.